دورية أكاديمية
أعرض في EDS

Analysis of polyunsaturated fatty acids in antipsychotic-free individuals with at-risk mental state and patients with first-episode schizophrenia.

التفاصيل البيبلوغرافية
العنوان: Analysis of polyunsaturated fatty acids in antipsychotic-free individuals with at-risk mental state and patients with first-episode schizophrenia.
المؤلفون: Le ATP; Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.; Research Center for Idling Brain Science, University of Toyama, Toyama, Japan., Higuchi Y; Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.; Research Center for Idling Brain Science, University of Toyama, Toyama, Japan.; Department of Preventive Intervention for Psychiatric Disorders, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan., Sumiyoshi T; Department of Preventive Intervention for Psychiatric Disorders, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.; Department of Psychiatry, National Center of Neurology and Psychiatry Hospital, Tokyo, Japan., Itoh H; Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan., Sasabayashi D; Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.; Research Center for Idling Brain Science, University of Toyama, Toyama, Japan., Takahashi T; Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.; Research Center for Idling Brain Science, University of Toyama, Toyama, Japan., Suzuki M; Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.; Research Center for Idling Brain Science, University of Toyama, Toyama, Japan.
المصدر: Frontiers in psychiatry [Front Psychiatry] 2023 Jul 26; Vol. 14, pp. 1188452. Date of Electronic Publication: 2023 Jul 26 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101545006 Publication Model: eCollection Cited Medium: Print ISSN: 1664-0640 (Print) Linking ISSN: 16640640 NLM ISO Abbreviation: Front Psychiatry Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Switzerland : Frontiers Research Foundation, 2010-
مستخلص: Introduction: Abnormalities in membrane phospholipids are considered one of the pathophysiological backgrounds for schizophrenia. This study, explores the fatty acid composition of erythrocyte membranes and its association with clinical characteristics in two groups: individuals with an at-risk mental state (ARMS) and patients experiencing their first-episode of schizophrenia (FES).
Materials and Methods: This study measured erythrocyte membrane fatty acids in 72 antipsychotic-free individuals with ARMS, 18 antipsychotic-free patients with FES, and 39 healthy volunteers. Clinical symptoms and cognitive and social functions were assessed using the Positive and Negative Syndrome Scale (PANSS), Brief Assessment of Cognition in Schizophrenia (BACS), Schizophrenia Cognition Rating Scale (SCoRS), and Social and Occupational Functioning Assessment Scale (SOFAS).
Results: Eicosapentaenoic and docosapentaenoic acid levels were lower in the ARMS and FES groups than in the healthy control group. In contrast, nervonic acid (NA) levels were markedly higher in the ARMS and FES groups than in the controls, while only the FES group showed higher levels of arachidonic acid. Oleic acid and NA levels were significantly associated with PANSS scores in both the FES and ARMS groups, particularly for the negative and general subscores. However, the patient groups had no significant associations between the fatty acid composition and the BACS, SCoRS, and SOFAS scores. Furthermore, the baseline fatty acid composition did not differ between the ARMS individuals who later developed psychosis ( N  = 6) and those who were followed for more than 2 years without developing psychosis onset ( N  = 30).
Discussion: The findings suggest that abnormal fatty acid compositions may be shared in the early stages of schizophrenia and the clinical high-risk state for psychosis and may serve as vulnerability markers of psychopathology.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2023 Le, Higuchi, Sumiyoshi, Itoh, Sasabayashi, Takahashi and Suzuki.)
References: Transl Psychiatry. 2022 Aug 20;12(1):340. (PMID: 35987687)
Prostaglandins Leukot Essent Fatty Acids. 2000 Jul-Aug;63(1-2):47-59. (PMID: 10970713)
Schizophr Res Cogn. 2015 Dec 17;2(4):172-178. (PMID: 29114461)
Schizophr Bull. 1987;13(2):261-76. (PMID: 3616518)
Psychiatry Clin Neurosci. 2007 Dec;61(6):602-9. (PMID: 18081619)
Schizophr Res. 1998 Apr 10;30(3):193-208. (PMID: 9589514)
PLoS One. 2016 Mar 10;11(3):e0151417. (PMID: 26963912)
Food Chem. 2019 Dec 15;301:125286. (PMID: 31382110)
Schizophr Bull. 2013 Jul;39(4):830-8. (PMID: 22927668)
Biol Psychiatry. 2020 Feb 1;87(3):243-252. (PMID: 31690495)
Prev Med. 2004 Jul;39(1):212-20. (PMID: 15208005)
Front Psychiatry. 2021 Nov 25;12:777378. (PMID: 34899430)
Schizophr Bull. 2016 Mar;42(2):358-68. (PMID: 26385764)
J Nutr. 1986 May;116(5):718-25. (PMID: 2871142)
Schizophr Res. 2007 Mar;91(1-3):37-50. (PMID: 17236749)
Biol Psychiatry. 2000 Jan 1;47(1):8-21. (PMID: 10650444)
Neurosci Biobehav Rev. 2021 Sep;128:90-101. (PMID: 34119524)
Eur Psychiatry. 2017 Jan;39:51-56. (PMID: 27821355)
Schizophr Res. 2004 Jun 1;68(2-3):283-97. (PMID: 15099610)
Biochim Biophys Acta Biomembr. 2023 Feb;1865(2):184084. (PMID: 36368636)
Psychiatry Res. 2015 Jul 30;228(1):174-6. (PMID: 25979466)
Biol Psychiatry. 2003 Jan 1;53(1):56-64. (PMID: 12513945)
J Affect Disord. 2022 Dec 1;318:414-422. (PMID: 36113689)
J Lipid Res. 1990 Feb;31(2):237-47. (PMID: 2139096)
Psychiatry Res. 2003 Dec 1;121(2):109-22. (PMID: 14656446)
Arch Gen Psychiatry. 2010 Feb;67(2):146-54. (PMID: 20124114)
Psychiatry Res. 2008 Jan 15;157(1-3):87-93. (PMID: 17976738)
Prostaglandins Leukot Essent Fatty Acids. 2010 Sep;83(3):131-6. (PMID: 20667702)
Early Interv Psychiatry. 2021 Aug;15(4):874-881. (PMID: 32893462)
Sci Rep. 2022 Apr 22;12(1):6652. (PMID: 35459763)
Front Psychiatry. 2019 Jun 06;10:393. (PMID: 31244693)
Epigenomics. 2012 Jun;4(3):303-15. (PMID: 22690666)
Behav Brain Res. 2001 Nov 1;125(1-2):279-84. (PMID: 11682119)
Psychiatry Res. 2011 Mar 30;186(1):23-7. (PMID: 20800904)
JAMA Psychiatry. 2013 Jan;70(1):107-20. (PMID: 23165428)
J Psychiatr Res. 2016 Feb;73:34-44. (PMID: 26679763)
Biol Psychiatry. 2001 Mar 15;49(6):510-22. (PMID: 11257236)
Gen Psychiatr. 2022 Apr 13;35(2):e100703. (PMID: 35531577)
Aust N Z J Psychiatry. 2005 Nov-Dec;39(11-12):964-71. (PMID: 16343296)
Biol Psychiatry. 2002 Oct 15;52(8):823-30. (PMID: 12372654)
Schizophr Res. 2014 Sep;158(1-3):39-44. (PMID: 25066495)
Front Psychiatry. 2018 Nov 09;9:574. (PMID: 30473669)
Schizophr Res. 2020 Dec;226:44-51. (PMID: 31301881)
Transl Psychiatry. 2016 Sep 20;6(9):e897. (PMID: 27648919)
Biol Psychiatry. 2003 Mar 1;53(5):431-41. (PMID: 12614996)
Cell Metab. 2020 Apr 7;31(4):755-772.e7. (PMID: 32142670)
Biochim Biophys Acta. 2015 Apr;1851(4):469-84. (PMID: 25149823)
Am J Psychiatry. 2006 Mar;163(3):426-32. (PMID: 16513863)
Schizophr Res. 2021 Feb;228:324-326. (PMID: 33497908)
Schizophr Bull. 1996;22(2):283-303. (PMID: 8782287)
Schizophr Bull. 2016 Jul;42(4):1018-26. (PMID: 26656881)
Curr Opin Psychiatry. 2013 Mar;26(2):172-87. (PMID: 23324948)
Schizophr Bull. 2013 Jul;39(4):923-32. (PMID: 22589370)
Nutrients. 2018 Nov 16;10(11):. (PMID: 30453550)
Am J Psychiatry. 1992 Sep;149(9):1148-56. (PMID: 1386964)
Prostaglandins Leukot Essent Fatty Acids. 2003 Dec;69(6):393-9. (PMID: 14623492)
Arch Gen Psychiatry. 2012 Mar;69(3):220-9. (PMID: 22393215)
Arch Gen Psychiatry. 1996 Jan;53(1):25-31. (PMID: 8540774)
Schizophr Bull. 2004;30(4):901-11. (PMID: 15957200)
Mol Psychiatry. 2012 Dec;17(12):1150-2. (PMID: 22182937)
Psychiatry Clin Neurosci. 2006 Jun;60(3):332-9. (PMID: 16732750)
Curr Opin Neurobiol. 2016 Feb;36:23-30. (PMID: 26363129)
Schizophr Res. 2002 Nov 1;58(1):1-10. (PMID: 12363384)
Schizophr Res Cogn. 2017 Feb 22;7:13-18. (PMID: 28740824)
Transl Psychiatry. 2017 Sep 5;7(9):e1229. (PMID: 28872641)
Mol Psychiatry. 2014 Mar;19(3):317-24. (PMID: 23478748)
PLoS One. 2015 Sep 01;10(9):e0136542. (PMID: 26325577)
Schizophr Res. 2012 Nov;141(2-3):153-61. (PMID: 22981812)
فهرسة مساهمة: Keywords: at-risk mental state; first-episode schizophrenia; n-3 polyunsaturated fatty acid; n-6 polyunsaturated fatty acid; nervonic acid; omega-3 polyunsaturated fatty acid; omega-6 polyunsaturated fatty acid; polyunsaturated fatty acid
تواريخ الأحداث: Date Created: 20230811 Latest Revision: 20230812
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10410072
DOI: 10.3389/fpsyt.2023.1188452
PMID: 37564244
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-0640
DOI:10.3389/fpsyt.2023.1188452